Cargando…
Development of an oncogenic dedifferentiation SOX signature with prognostic significance in hepatocellular carcinoma
BACKGROUND: Gradual loss of terminal differentiation markers and gain of stem cell-like properties is a major hall mark of cancer malignant progression. The stem cell pluripotent transcriptional factor SOX family play critical roles in governing tumor plasticity and lineage specification. This study...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6714407/ https://www.ncbi.nlm.nih.gov/pubmed/31462277 http://dx.doi.org/10.1186/s12885-019-6041-2 |
_version_ | 1783447061873557504 |
---|---|
author | Li, Mei-Mei Tang, Yun-Qiang Gong, Yuan-Feng Cheng, Wei Li, Hao-Long Kong, Fan-En Zhu, Wen-Jie Liu, Shan-Shan Huang, Li Guan, Xin-Yuan Ma, Ning-Fang Liu, Ming |
author_facet | Li, Mei-Mei Tang, Yun-Qiang Gong, Yuan-Feng Cheng, Wei Li, Hao-Long Kong, Fan-En Zhu, Wen-Jie Liu, Shan-Shan Huang, Li Guan, Xin-Yuan Ma, Ning-Fang Liu, Ming |
author_sort | Li, Mei-Mei |
collection | PubMed |
description | BACKGROUND: Gradual loss of terminal differentiation markers and gain of stem cell-like properties is a major hall mark of cancer malignant progression. The stem cell pluripotent transcriptional factor SOX family play critical roles in governing tumor plasticity and lineage specification. This study aims to establish a novel SOX signature to monitor the extent of tumor dedifferentiation and predict prognostic significance in hepatocellular carcinoma (HCC). METHODS: The RNA-seq data from The Cancer Genome Atlas (TCGA) LIHC project were chronologically divided into the training (n = 188) and testing cohort (n = 189). LIRI-JP project from International Cancer Genome Consortium (ICGC) data portal was used as an independent validation cohort (n = 232). Kaplan-Meier and multivariable Cox analyses were used to examine the clinical significance and prognostic value of the signature genes. RESULTS: The SOX gene family members were found to be aberrantly expressed in clinical HCC patients. A five-gene SOX signature with prognostic value was established in the training cohort. The SOX signature genes were found to be closely associated with tumor grade and tumor stage. Liver cancer dedifferentiation markers (AFP, CD133, EPCAM, and KRT19) were found to be progressively increased while hepatocyte terminal differentiation markers (ALB, G6PC, CYP3A4, and HNF4A) were progressively decreased from HCC patients with low SOX signature scores to patients with high SOX signature scores. Kaplan-Meier survival analysis further indicated that the newly established SOX signature could robustly predict patient overall survival in both training, testing, and independent validation cohort. CONCLUSIONS: An oncogenic dedifferentiation SOX signature presents a great potential in predicting prognostic significance in HCC, and might provide novel biomarkers for precision oncology further in the clinic. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12885-019-6041-2) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-6714407 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-67144072019-09-04 Development of an oncogenic dedifferentiation SOX signature with prognostic significance in hepatocellular carcinoma Li, Mei-Mei Tang, Yun-Qiang Gong, Yuan-Feng Cheng, Wei Li, Hao-Long Kong, Fan-En Zhu, Wen-Jie Liu, Shan-Shan Huang, Li Guan, Xin-Yuan Ma, Ning-Fang Liu, Ming BMC Cancer Research Article BACKGROUND: Gradual loss of terminal differentiation markers and gain of stem cell-like properties is a major hall mark of cancer malignant progression. The stem cell pluripotent transcriptional factor SOX family play critical roles in governing tumor plasticity and lineage specification. This study aims to establish a novel SOX signature to monitor the extent of tumor dedifferentiation and predict prognostic significance in hepatocellular carcinoma (HCC). METHODS: The RNA-seq data from The Cancer Genome Atlas (TCGA) LIHC project were chronologically divided into the training (n = 188) and testing cohort (n = 189). LIRI-JP project from International Cancer Genome Consortium (ICGC) data portal was used as an independent validation cohort (n = 232). Kaplan-Meier and multivariable Cox analyses were used to examine the clinical significance and prognostic value of the signature genes. RESULTS: The SOX gene family members were found to be aberrantly expressed in clinical HCC patients. A five-gene SOX signature with prognostic value was established in the training cohort. The SOX signature genes were found to be closely associated with tumor grade and tumor stage. Liver cancer dedifferentiation markers (AFP, CD133, EPCAM, and KRT19) were found to be progressively increased while hepatocyte terminal differentiation markers (ALB, G6PC, CYP3A4, and HNF4A) were progressively decreased from HCC patients with low SOX signature scores to patients with high SOX signature scores. Kaplan-Meier survival analysis further indicated that the newly established SOX signature could robustly predict patient overall survival in both training, testing, and independent validation cohort. CONCLUSIONS: An oncogenic dedifferentiation SOX signature presents a great potential in predicting prognostic significance in HCC, and might provide novel biomarkers for precision oncology further in the clinic. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12885-019-6041-2) contains supplementary material, which is available to authorized users. BioMed Central 2019-08-28 /pmc/articles/PMC6714407/ /pubmed/31462277 http://dx.doi.org/10.1186/s12885-019-6041-2 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Li, Mei-Mei Tang, Yun-Qiang Gong, Yuan-Feng Cheng, Wei Li, Hao-Long Kong, Fan-En Zhu, Wen-Jie Liu, Shan-Shan Huang, Li Guan, Xin-Yuan Ma, Ning-Fang Liu, Ming Development of an oncogenic dedifferentiation SOX signature with prognostic significance in hepatocellular carcinoma |
title | Development of an oncogenic dedifferentiation SOX signature with prognostic significance in hepatocellular carcinoma |
title_full | Development of an oncogenic dedifferentiation SOX signature with prognostic significance in hepatocellular carcinoma |
title_fullStr | Development of an oncogenic dedifferentiation SOX signature with prognostic significance in hepatocellular carcinoma |
title_full_unstemmed | Development of an oncogenic dedifferentiation SOX signature with prognostic significance in hepatocellular carcinoma |
title_short | Development of an oncogenic dedifferentiation SOX signature with prognostic significance in hepatocellular carcinoma |
title_sort | development of an oncogenic dedifferentiation sox signature with prognostic significance in hepatocellular carcinoma |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6714407/ https://www.ncbi.nlm.nih.gov/pubmed/31462277 http://dx.doi.org/10.1186/s12885-019-6041-2 |
work_keys_str_mv | AT limeimei developmentofanoncogenicdedifferentiationsoxsignaturewithprognosticsignificanceinhepatocellularcarcinoma AT tangyunqiang developmentofanoncogenicdedifferentiationsoxsignaturewithprognosticsignificanceinhepatocellularcarcinoma AT gongyuanfeng developmentofanoncogenicdedifferentiationsoxsignaturewithprognosticsignificanceinhepatocellularcarcinoma AT chengwei developmentofanoncogenicdedifferentiationsoxsignaturewithprognosticsignificanceinhepatocellularcarcinoma AT lihaolong developmentofanoncogenicdedifferentiationsoxsignaturewithprognosticsignificanceinhepatocellularcarcinoma AT kongfanen developmentofanoncogenicdedifferentiationsoxsignaturewithprognosticsignificanceinhepatocellularcarcinoma AT zhuwenjie developmentofanoncogenicdedifferentiationsoxsignaturewithprognosticsignificanceinhepatocellularcarcinoma AT liushanshan developmentofanoncogenicdedifferentiationsoxsignaturewithprognosticsignificanceinhepatocellularcarcinoma AT huangli developmentofanoncogenicdedifferentiationsoxsignaturewithprognosticsignificanceinhepatocellularcarcinoma AT guanxinyuan developmentofanoncogenicdedifferentiationsoxsignaturewithprognosticsignificanceinhepatocellularcarcinoma AT maningfang developmentofanoncogenicdedifferentiationsoxsignaturewithprognosticsignificanceinhepatocellularcarcinoma AT liuming developmentofanoncogenicdedifferentiationsoxsignaturewithprognosticsignificanceinhepatocellularcarcinoma |